Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.
INTRODUCTION Real-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR. This post hoc analysis investigated the use of combination semaglutide-sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment, glycated hemoglobin (HbA1c) changes, and safety in a subset of SCH...